Trial Profile
Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Regrelor (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 04 Aug 2011 New trial record